HemeHub

Paul Richardson, MD is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, and the RJ Corman Professor of Medicine at Harvard Medical School. A leading authority in the treatment of multiple myeloma, Paul Richardson, MD has been instrumental in advancing novel therapies that have transformed patient outcomes. His work has been central to the development and approval of groundbreaking agents, including thalidomide, lenalidomide, bortezomib, pomalidomide, panobinostat, elotuzumab, daratumumab, and more recently, ixazomib, selinexor, and mezigdomide. Paul Richardson, MD has led numerous pivotal trials that have reshaped standards of care, most notably the VISTA trial, which established bortezomib-based therapy as frontline treatment, and the international DETERMINATION study, which helped define the role of autologous stem cell transplantation in the era of novel agents. His research integrates translational science with clinical innovation, exploring combinations of small molecules, targeted therapies, and immunotherapeutics to optimize outcomes for patients across the spectrum of multiple myeloma. In addition to his research, Paul Richardson, MD is deeply committed to patient care and mentorship. He has authored or co-authored hundreds of peer-reviewed publications, reviews, and book chapters, and is widely recognized as an educator and thought leader in hematology-oncology. His contributions have been honored with numerous awards, including recognition for excellence in teaching, clinical research, and innovation in cancer care. Through his leadership, Paul Richardson, MD continues to advance the field of myeloma therapy while improving the lives of patients worldwide.